Alembic Pharmaceuticals

Alembic Pharmaceuticals, an Indian pharmaceutical preparation manufacturer, reported a total of approximately 761,178,896 kg CO2e for the year 2025. This figure encompasses Scope 1, Scope 2, and Scope 3 emissions. Scope 3 emissions were the largest contributor, accounting for approximately 602,934,950 kg CO2e, with purchased goods and services representing a significant portion of this. Scope 1 emissions were approximately 80,278,030 kg CO2e, and Scope 2 emissions were approximately 77,965,980 kg CO2e.

For the previous year, 2024, Alembic Pharmaceuticals reported total emissions of approximately 824,980,000 kg CO2e. This included Scope 1 emissions of about 71,132,000 kg CO2e, Scope 2 emissions of approximately 67,544,000 kg CO2e, and Scope 3 emissions totalling approximately 686,304,000 kg CO2e.

Alembic Pharmaceuticals has set ambitious climate targets. The company aims to reduce its greenhouse gas (GHG) emissions by 63% by FY2034, using FY2022 as a baseline. Furthermore, they are committed to achieving net-zero GHG emissions across their value chain by FY2050, with a target of reducing emissions by 90% by the same year from the FY2022 baseline. These targets are aligned with a 1.5°C warming pathway.